妊娠期肝病临床研究进展

肖鹏; 巴桃桃; 丁梦梦; 高沿航

doi:10.3969/j.issn.1001-5256.2021.05.054

妊娠期肝病临床研究进展

DOI: 10.3969/j.issn.1001-5256.2021.05.054

吉林大学第一医院肝胆胰内科，长春 130021

基金项目:

国家自然科学基金 (81972265);

吉林省自然科学基金 (20200201324JC)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：肖鹏负责课题设计，资料分析，撰写论文；巴桃桃、丁梦梦参与收集数据，修改论文；高沿航负责拟定写作思路，指导撰写文章并最后定稿。

详细信息

作者简介:
肖鹏(1994—)，女，主要从事肝病研究

通信作者:
高沿航，yanhang@mail.jlu.edu.cn

中图分类号: R714.255
计量
- 文章访问数: 704
- HTML全文浏览量: 283
- PDF下载量: 135
- 被引次数: 0
出版历程
- 收稿日期: 2020-12-08
- 录用日期: 2021-01-20
- 出版日期: 2021-05-20

Advances in clinical research on liver disease during pregnancy

Department of Hepatology, The First Hospital of Jilin University, Changchun 130021, China

摘要

摘要: 根据肝损伤与妊娠的关系可将妊娠期肝病分为妊娠期特异性肝病和肝病合并妊娠。妊娠期特异性肝病指的是只发生在妊娠期的肝脏疾病，而肝病合并妊娠指的是既往肝脏疾病基础上合并妊娠。由于妊娠期涉及母亲和胎儿健康的特殊性，妊娠期肝病的诊治对产科和肝病科医生都具有一定挑战性。在妊娠过程中迅速识别诊断及处理相关疾病，对母亲和胎儿预后十分重要。总结评述了妊娠期肝病的流行病学、发病机制、临床表现、诊断治疗、预后等方面研究进展，以期为更多临床医生提供给参考。
- 肝疾病 /
- 妊娠 /
- 孕妇
Abstract: According to the association between liver injury and pregnancy, liver diseases during pregnancy can be classified as pregnancy-specific liver diseases and liver diseases with pregnancy. Pregnancy-specific liver diseases refer to the liver diseases that only occur during pregnancy, while liver diseases with pregnancy refer to pregnancy with previous liver diseases. Due to the particularity of maternal and fetal health during pregnancy, the diagnosis and treatment of liver diseases during pregnancy is challenging for both obstetricians and hepatologists. Rapid identification, diagnosis, and treatment of related diseases during pregnancy are very important for the prognosis of the mother and the fetus. This article summarizes and reviews the research advances in the epidemiology, pathogenesis, clinical manifestations, diagnosis, treatment, and prognosis of liver diseases during pregnancy, in order to provide a reference for more clinicians.
- Liver Diseases /
- Pregnancy /
- Pregnant Women

HTML全文

参考文献(26)

[1]	MEHER S, DULEY L, HUNTER K, et al. Antiplatelet therapy before or after 16 weeks' gestation for preventing preeclampsia: An individual participant data meta-analysis[J]. Am J Obstet Gynecol, 2017, 216(2): 121-128. e2. DOI: 10.1016/j.ajog.2016.10.016.
[2]	BRADY CW. Liver disease in pregnancy: What's new[J]. Hepatol Commun, 2020, 4(2): 145-156. DOI: 10.1002/hep4.1470.
[3]	ROBERGE S, NICOLAIDES K, DEMERS S, et al. The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: Systematic review and meta-analysis[J]. Am J Obstet Gynecol, 2017, 216(2): 110-120. e6. DOI: 10.1016/j.ajog.2016.09.076.
[4]	American College of Obstetrician and Gynecologists. ACOG Practice Bulletin No. 202: Gestational hypertension and preeclampsia[J]. Obstet Gynecol, 2019, 133(1): 1-25. DOI: 10.1097/AOG.0000000000003018.
[5]	GAO Q, QU X, CHEN X, et al. Outcomes and risk factors of patients with acute fatty liver of pregnancy: A multicentre retrospective study[J]. Singapore Med J, 2018, 59(8): 425-430. DOI: 10.11622/smedj.2018001.
[6]	SHEKHAR S, DIDDI G. Liver disease in pregnancy[J]. Taiwan J Obstet Gynecol, 2015, 54(5): 475-482. DOI: 10.1016/j.tjog.2015.01.004.
[7]	WESTBROOK RH, DUSHEIKO G, WILLIAMSON C. Pregnancy and liver disease[J]. J Hepatol, 2016, 64(4): 933-945. DOI: 10.1016/j.jhep.2015.11.030.
[8]	Italian Association for the Study of the Liver (AISF), Italian Association for the Study of the Liver AISF. AISF position paper on liver disease and pregnancy[J]. Dig Liver Dis, 2016, 48(2): 120-137. DOI: 10.1016/j.dld.2015.11.004.
[9]	LIU J, GHAZIANI TT, WOLF JL. Acute fatty liver disease of pregnancy: Updates in pathogenesis, diagnosis, and management[J]. Am J Gastroenterol, 2017, 112(6): 838-846. DOI: 10.1038/ajg.2017.54.
[10]	CH'NG CL, MORGAN M, HAINSWORTH I, et al. Prospective study of liver dysfunction in pregnancy in Southwest Wales[J]. Gut, 2002, 51(6): 876-880. DOI: 10.1136/gut.51.6.876.
[11]	SMITH DD, ROOD KM. Intrahepatic cholestasis of pregnancy[J]. Clin Obstet Gynecol, 2020, 63(1): 134-151. DOI: 10.1097/GRF.0000000000000495.
[12]	OZKAN S, CEYLAN Y, OZKAN OV, et al. Review of a challenging clinical issue: Intrahepatic cholestasis of pregnancy[J]. World J Gastroenterol, 2015, 21(23): 7134-7141. DOI: 10.3748/wjg.v21.i23.7134.
[13]	OVADIA C, SEED PT, SKLAVOUNOS A, et al. Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: Results of aggregate and individual patient data meta-analyses[J]. Lancet, 2019, 393(10174): 899-909. DOI: 10.1016/S0140-6736(18)31877-4.
[14]	SMOLARCZYK R, GRYMOWICZ M, SIENKO J, et al. Successful perinatal outcome in an early onset intrahepatic cholestasis of pregnancy with extremely high serum hepatic function tests[J]. Gynecol Endocrinol, 2009, 25(7): 475-476. DOI: 10.1080/09513590902945147.
[15]	Obstetrics Subgroup, Chinese Society of Obstetrics and Gynecology, Chinese Medical Association. Guidelines for the management of intrahepatic cholestasis of pregnancy(2015)[J]. J Clin Hepatol, 2015, 31(10): 1575-1578. DOI: 10.3969/j.issn.1001-5256.2015.10.003. 中华医学会妇产科学分会产科学组. 妊娠期肝内胆汁淤积症诊疗指南(2015)[J]. 临床肝胆病杂志, 2015, 31(10): 1575-1578. DOI: 10.3969/j.issn.1001-5256.2015.10.003.
[16]	CHAPPELL LC, BELL JL, SMITH A, et al. Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): A randomised controlled trial[J]. Lancet, 2019, 394(10201): 849-860. DOI: 10.1016/S0140-6736(19)31270-X.
[17]	BINDER T, SALAJ P, ZIMA T, et al. Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy[J]. J Perinat Med, 2006, 34(5): 383-391. DOI: 10.1515/JPM.2006.077.
[18]	TERRAULT NA, LOK A, MCMAHON BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67(4): 1560-1599. DOI: 10.1002/hep.29800.
[19]	Obstetrics Subgroup, Chinese Society of Obstetrics and Gynecology, Chinese Medical Association; Chinese Society of Perinatal Medicine, Chinese Medical Association. 2020 clinical guidelines on prevention of mother-to-child transmission of hepatitis B virus[J]. J Clin Hepatol, 2020, 36(7): 1474-1481. DOI: 10.3760/cma.j.cn112141-20200213-00101. 中华医学会妇产科学分会产科学组, 中华医学会围产医学分会. 乙型肝炎病毒母婴传播预防临床指南(2020)[J]. 临床肝胆病杂志, 2020, 36(7): 1474-1481. DOI: 10.3760/cma.j.cn112141-20200213-00101.
[20]	CONNELL LE, SALIHU HM, SALEMI JL, et al. Maternal hepatitis B and hepatitis C carrier status and perinatal outcomes[J]. Liver Int, 2011, 31(8): 1163-1170. DOI: 10.1111/j.1478-3231.2011.02556.x.
[21]	PERGAM SA, WANG CC, GARDELLA CM, et al. Pregnancy complications associated with hepatitis C: Data from a 2003-2005 Washington state birth cohort[J]. Am J Obstet Gynecol, 2008, 199(1): 38. e1-9. DOI: 10.1016/j.ajog.2008.03.052.
[22]	MAST EE, HWANG LY, SETO DS, et al. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy[J]. J Infect Dis, 2005, 192(11): 1880-1889. DOI: 10.1086/497701.
[23]	CHAPPELL CA, SCARSI KK, KIRBY BJ, et al. Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: A phase 1 pharmacokinetic study[J]. Lancet Microbe, 2020, 1(5): e200-e208. DOI: 10.1016/S2666-5247(20)30062-8.
[24]	GARCIA-TSAO G, ABRALDES JG, BERZIGOTTI A, et al. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases[J]. Hepatology, 2017, 65(1): 310-335. DOI: 10.1002/hep.28906.
[25]	JUNG YM, LEE SM, HONG S, et al. The risk of pregnancy-associated hypertension in women with nonalcoholic fatty liver disease[J]. Liver Int, 2020, 40(10): 2417-2426. DOI: 10.1111/liv.14563.
[26]	LEE SM, KWAK SH, KOO JN, et al. Non-alcoholic fatty liver disease in the first trimester and subsequent development of gestational diabetes mellitus[J]. Diabetologia, 2019, 62(2): 238-248. DOI: 10.1007/s00125-018-4779-8.